Chen Shiping 4

4 · Alamar Biosciences, Inc. · Filed Apr 20, 2026

Research Summary

AI-generated summary of this filing

Updated Apr 21, 2026

Alamar Biosciences (ALMR) COO Chen Shiping Converts Derivatives, Receives RSUs

What Happened

Chen Shiping, Chief Operating Officer of Alamar Biosciences (ALMR), reported multiple non‑cash transactions dated April 16–20, 2026. The filing shows conversions of derivative securities into common stock and the receipt of restricted stock unit (RSU) awards. Reported activity includes acquisitions and dispositions that appear to reflect reclassifications/conversions rather than open‑market trades — all reported at $0.00 or N/A.
Key reported amounts (per the Form 4): several conversion and reclassification entries totaling roughly 1.63 million shares acquired and roughly 1.53 million shares disposed (many entries pair a derivative disposal with an acquisition of common shares). Reported RSU grants include 163,358 (derivative RSU grant on 4/16) and 37,220 shares (4/20). No cash changed hands in the reported transactions.

Key Details

Dates & prices: Transactions dated April 16 and April 20, 2026; most entries reported at $0.00 or N/A, indicating non‑cash conversions/awards.
Transaction types: Codes include C = conversion of derivative security, A = grant/award (RSUs), J = other acquisition/disposition (used here for reclassifications).
Shares owned after transaction: Not specified in the summary provided.
Notable footnotes from the filing:
- F1–F3: Describes automatic conversion/reclassification of Class A, Founders Preferred, Series A‑1 Preferred and Class B shares into the common stock around the IPO (mechanical recapitalization).
- F4: RSUs vest monthly from grant date, subject to continued service.
- F5–F7: Describe vesting schedules for various option grants (monthly/annual vesting schedules).
Filing timeliness: Form 4 was filed April 20, 2026 and reports transactions dated April 16–20; no late‑filing flag is indicated in the provided data.

Context

These entries appear to be corporate conversions and award vesting/reclassification tied to the IPO and equity plan mechanics (not open‑market buys or cash sales). Zero‑dollar and N/A lines commonly mean conversion of previously held preferred/other share classes into common stock or issuance of RSUs, not an indication of a cash purchase or sale.
For retail investors: such mechanical conversions and RSU grants are routine following IPOs or capital structure changes and do not necessarily signal a change in insider sentiment.

Insider Transaction Report

Form 4

Period: 2026-04-16

Alamar Biosciences, Inc.ALMR

Chen Shiping

DirectorChief Operating Officer

Transactions

Conversion
Class B Common Stock
[F1]
2026-04-20+320,511→ 650,032 total
Conversion
Class B Common Stock
[F2]
2026-04-20+72,853→ 722,885 total
Other
Class B Common Stock
[F3]
2026-04-20−722,885→ 0 total
Other
Common Stock
[F3]
2026-04-20+722,885→ 722,885 total
Award
Common Stock
[F4]
2026-04-20+37,220→ 760,105 total
Award
Stock Option (Right to Buy)
[F5]
2026-04-16+163,358→ 163,358 total
Exercise: $17.00Exp: 2036-04-15→ Common Stock (163,358 underlying)
Conversion
Class A Common Stock
[F1]
2026-04-20−247,311→ 0 total
→ Class B Common Stock (247,311 underlying)
Conversion
Founders Preferred Stock
[F1]
2026-04-20−73,200→ 0 total
→ Class B Common Stock (73,200 underlying)
Conversion
Series A-1 Preferred Stock
[F2]
2026-04-20−176,160→ 0 total
→ Class B Common Stock (72,853 underlying)
Other
Stock Option (Right to Buy)
[F3][F6]
2026-04-20−300,883→ 0 total
Exercise: $3.34Exp: 2035-01-15→ Class B Common Stock (300,883 underlying)
Other
Stock Option (Right to Buy)
[F3][F6]
2026-04-20+300,883→ 300,883 total
Exercise: $3.34Exp: 2035-01-15→ Common Stock (300,883 underlying)
Other
Stock Option (Right to Buy)
[F3][F7]
2026-04-20−12,190→ 0 total
Exercise: $7.60Exp: 2036-01-14→ Class B Common Stock (12,190 underlying)
Other
Stock Option (Right to Buy)
[F3][F7]
2026-04-20+12,190→ 12,190 total
Exercise: $7.60Exp: 2036-01-14→ Common Stock (12,190 underlying)

Footnotes (7)

[F1]The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO").
[F2]The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO.
[F3]Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.
[F4]Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date.
[F5]Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.
[F6]The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date.
[F7]The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date.

Signature

/s/ Timothy White, Attorney-in-Fact|2026-04-20

Documents

1 file

4
form4-04212026_120439.xmlPrimary